Cytotoxicity of expanded/activated Vδ1+ T cells from CMV seropositive and seronegative healthy volunteers against human glioma cell lines.

<p>(<b><i>a</i></b>) Flow cytometric analysis of 14-day expansion culture of purified Vδ1+ T cells from two healthy volunteer donors. (<b><i>b</i></b>) Cytotoxicity of purified and expanded Vδ1+ T cells from two donors against three (left to right for each donor) GBM cell lines (<i>a</i>) U251, (<i>b</i>) U87, and (<i>c</i>) U373 and two primary cell lines from GBM explants designated (d)1016 and (<i>e</i>)1042 in a four-hour cytotoxicity assay at an E∶T ratio of 20∶1. (<b><i>c</i></b>) Vδ1+ T cell cultures were expanded from additional CMV-seropositive (n = 4) and CMV-seronegative (n = 6) donors as described in the text and reacted over 4 h at an E∶T ratio of 20∶1 is shown with the U251MG glioma cell line and the 1024 primary GBM explant line. Donor CMV serologic status had no effect on Vδ1+ T cell cytotoxicity against U251 (p = 0.75) or 1042 (p = 0.29), respectively for CMV seropositive and CMV seronegative donors.